Bendamustine

Generic Name
Bendamustine
Brand Names
Belrapzo, Bendeka, Treanda, Vivimusta
Drug Type
Small Molecule
Chemical Formula
C16H21Cl2N3O2
CAS Number
16506-27-7
Unique Ingredient Identifier
9266D9P3PQ
Background

Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophili...

Indication

Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Associated Conditions
Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
Associated Therapies
-
Clinical Trials
Related News

A Study of Bendamustine in the Treatment of Chinese Participants With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment

Phase 3
Completed
Conditions
Non-Hodgkin Lymphoma
Interventions
Drug: Bendamustine hydrochloride
First Posted Date
2012-05-11
Last Posted Date
2023-05-26
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
102
Registration Number
NCT01596621
Locations
🇨🇳

Teva Investigational Site 025, Hefei, China

🇨🇳

Teva Investigational Site 005, Shanghai, China

🇨🇳

Teva Investigational Site 009, Shenyang, China

and more 24 locations

A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma

First Posted Date
2012-05-09
Last Posted Date
2021-08-02
Lead Sponsor
AbbVie
Target Recruit Count
60
Registration Number
NCT01594229
Locations
🇺🇸

Johns Hopkins University /ID# 67345, Baltimore, Maryland, United States

🇺🇸

Emory University Hospital /ID# 67349, Atlanta, Georgia, United States

🇺🇸

Georgia Regents University /ID# 67342, Augusta, Georgia, United States

and more 5 locations

Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma

First Posted Date
2012-04-04
Last Posted Date
2012-08-02
Lead Sponsor
Shandong Lanjin Pharmaceuticals Co.,Ltd
Target Recruit Count
100
Registration Number
NCT01570049
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )

First Posted Date
2012-04-03
Last Posted Date
2020-03-10
Lead Sponsor
Gilead Sciences
Target Recruit Count
416
Registration Number
NCT01569295
Locations
🇺🇸

University of Florida, Gainesville, Florida, United States

🇬🇧

University College London, London, United Kingdom

🇬🇷

G. Genimatas Hospital, Athens, Greece

and more 101 locations

Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma

First Posted Date
2012-02-20
Last Posted Date
2021-11-19
Lead Sponsor
Beth Christian
Target Recruit Count
26
Registration Number
NCT01535924
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

🇺🇸

Ohio State University Medical Center, Columbus, Ohio, United States

Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM

First Posted Date
2012-02-06
Last Posted Date
2018-07-03
Lead Sponsor
Azienda Ospedaliera di Bolzano
Target Recruit Count
30
Registration Number
NCT01526694
Locations
🇮🇹

AULSS 2 Feltre, Feltre, Italy

🇮🇹

Ospedale Ca Foncello, Treviso, Italy

🇮🇹

Ospedale dell'Angelo di Mestre, Mestre, Italy

and more 16 locations

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

First Posted Date
2012-01-30
Last Posted Date
2017-01-19
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
99
Registration Number
NCT01520922
Locations
🇪🇸

Novartis Investigative Site, Majadahonda (Madrid), Spain

Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)

First Posted Date
2011-12-13
Last Posted Date
2020-05-05
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
20
Registration Number
NCT01490723
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma

Phase 1
Terminated
Conditions
Multiple Myeloma
Interventions
Drug: Bendamustine
First Posted Date
2011-12-02
Last Posted Date
2018-07-10
Lead Sponsor
Loyola University
Target Recruit Count
3
Registration Number
NCT01484626
Locations
🇺🇸

Loyola University Medical Center, Maywood, Illinois, United States

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

First Posted Date
2011-11-28
Last Posted Date
2024-02-13
Lead Sponsor
Kami Maddocks, MD
Target Recruit Count
48
Registration Number
NCT01479842
Locations
🇺🇸

Ohio State University Medical Center, Columbus, Ohio, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy